Acer Therapeutics Inc (NASDAQ:ACER)

CAPS Rating: 1 out of 5

A biopharmaceutical company developing autologous cellular therapies to treat several major illnesses, including multiple sclerosis, rheumatoid arthritis, diabetes, and cardiovascular disease.

Caps

How do you think ACER will perform against the market?

Add Stock to CAPS Watchlist

All Players

33 Outperform
22 Underperform
 

All-Star Players

3 Outperform
15 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top ACER Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

whoodatstockhot (75.26)
Submitted August 07, 2013

Cutting edge research being completed at Opexa, huge buyout potential here, one of those specs that could change how MS is treated. Balance sheet strong, low risk of secondary. Great risk reward, with over 500% upisde quite possible for long-term… More

jed71 (99.23)
Submitted November 07, 2016

Well, this certainly seems to shed light on some of their problems: "Opexa Therapeutics reduces workforce by 40% in light of the negative Phase 2b Abili-T clinical trial top-line results announced on October 28""Following further analysis of the… More

ACER VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about ACER.

Recs

0
Member Avatar TSIF (99.98) Submitted: 11/21/2016 3:01:55 PM : Underperform Start Price: $12.62 ACER Score: -38.78

As Jed71 noted this one has little left in the tank after it's lead drug candidate was squashed.

It laid off, cut expenses and says it has enough cash for it's few remaining employees to wind down the failed trial (Abili-T) and for "general purposes" into the first quarter. The first quarter is only about a month away.

Clearly the 80% rise, and climbing past my entry to a near double as I type is:
1. Someone knows something; (why a few million in cash, burning, and a failed drug portfolio is worth twice as much).
2. Speculating
3. Shorts covering, reupping, covering,
4. Day traders.

A combination of 2,3,4 above in repeating mode.

Target 0.20

Recs

3
Member Avatar jed71 (99.23) Submitted: 11/7/2016 10:24:32 AM : Underperform Start Price: $7.11 ACER Score: -161.14

Well, this certainly seems to shed light on some of their problems:

"Opexa Therapeutics reduces workforce by 40% in light of the negative Phase 2b Abili-T clinical trial top-line results announced on October 28"

"Following further analysis of the Phase 2b Abili-T clinical trial top-line results and in order to reduce operating expenses and conserve cash resources, on October 26, 2016, the Company's Board of Directors approved reduction of the Company's 20 current full-time employees. The workforce reduction is effective immediately. The Company estimates that it will incur incremental aggregate cash charges of approximately $95,000 associated with this workforce reduction. The Company also announced that it had accepted the resignation of Donna Rill, the Company's Chief Development Officer, with such resignation to be effective as of November 4, 2016."

I expect a reverse split will follow shortly, as well as a new cash raise after the reverse split takes place. That's assuming they can find anyone to sell additional shares to, which seems to be a bit of a stretch here. A little more dangerous than my normal red thumbs, but this should move much lower over the next 12 months or so. Target under $0.10 pre-split.

Recs

0
Member Avatar allstar31 (99.92) Submitted: 9/12/2014 11:14:52 PM : Underperform Start Price: $111.01 ACER Score: +119.32

Uses known stock pump and dumper Redchip.com for PR purposes. Garbage.

Leaderboard

Find the members with the highest scoring picks in ACER.

Score Leader

whatsthepoint

whatsthepoint (99.98) Score: +220.18

The Score Leader is the player with the highest score across all their picks in ACER.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
MaxPwr273 68.65 10/26/2011 Underperform 5Y $364.50 -94.33% +120.41% +214.74 0 Comment
2011Fool 98.44 2/18/2011 Underperform NS $632.90 -96.73% +104.47% +201.20 0 Comment
saab93boi 21.68 3/26/2013 Underperform 3W $211.24 -90.21% +76.04% +166.25 0 Comment
Halffrenzy 25.33 3/13/2013 Underperform 5Y $178.11 -88.39% +76.39% +164.78 0 Comment
Mary953 85.18 3/25/2013 4/6/2018 Underperform 5Y $173.14 -88.06% +76.10% +164.16 0 Comment
stockjock11 < 20 5/22/2013 Underperform 5Y $138.34 -85.05% +63.03% +148.08 0 Comment
allstar31 99.92 9/15/2014 Underperform 5Y $111.01 -81.37% +37.95% +119.32 1 Comment
hayrettin 70.99 12/21/2017 Outperform 5Y $13.83 +49.57% +2.67% +46.91 0 Comment
johnnyrocku 99.91 10/16/2017 Underperform 5Y $18.69 +10.68% +7.74% -2.94 0 Comment
anchak 99.89 10/10/2017 Underperform NS $17.80 +16.18% +7.91% -8.27 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackMDB < 20 2/20/2007 Outperform NS $1,457.98 -85.91% -5.14% -80.77 4/17/2012 @ $205.41 0 Comment

Featured Broker Partners


Advertisement